Oncology is one island where biotech investment continues in the sea of shrinking biopharma. As expected, the current environment is also conducive to oncology biotech companies being lost to mergers and acquisitions. Sadly, these carefully crafted and nurtured brands will be lost for ever!
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label mapk. Show all posts
Showing posts with label mapk. Show all posts
Saturday, December 31, 2011
Friday, October 15, 2010
Five year anniversary of Nexavar® (sorafenib) approval by FDA
In about two months, five days before Christmas, sorafenib will celebrate five years of approval by the FDA. When it was approved on December 20th, 2005, for advanced Renal Cell Carcinoma (RCC), it was the first (and is so far the only) approved drug to target B-Raf kinase, a signaling component of the MAPK pathway. Since then it has also been approved for Hepatocellular Carcinoma (HCC).
Subscribe to:
Posts (Atom)